The Influence of Treatment With Sofosbuvir/Velpatasvir on Children’s Growth—Results of the PANDAA-PED Study DOI
Maria Pokorska‐Śpiewak, Ewa Talarek, Małgorzata Aniszewska

et al.

The Pediatric Infectious Disease Journal, Journal Year: 2024, Volume and Issue: 44(1), P. 1 - 5

Published: Sept. 4, 2024

Background: The aim of this study was to evaluate the influence treatment hepatitis C with sofosbuvir and velpatasvir (SOF/VEL) on children’s growth. Methods: Fifty children 6-18 years age were successfully treated for a 12-week course SOF/VEL fixed dose adjusted body weight in PANDAA-PED (Treatment chronic 6–18 using pangenotypic direct-acting antiviral sofosbuvir/velpatasvir) project. Growth parameters compared at 1 year after baseline (at start treatment) 12-week-posttreatment values. Body mass index (BMI), height Z scores sex calculated according World Health Organization reference data. Results: Forty-nine participants (23 boys 26 girls) completed all visits. mean 10.9 ± 2.5 years, had undetectable virus RNA point. Significant gains observed irrespective patients’ sex. Height did not vary significantly both 12 weeks treatment, confirming normal increase participants’ height. Weight 16 below 10 decreased treatment. BMI score values boys, but no difference found between 1-year posttreatment girls boys. Conclusions: Results showed growth up successful age. Despite decrease differences Our observations confirm long-term safety

Language: Английский

Hepatitis C virus and hepatocellular carcinoma: carcinogenesis in the era of direct-acting antivirals DOI Creative Commons

Felix Fiehn,

Claudia Beisel,

Marco Binder

et al.

Current Opinion in Virology, Journal Year: 2024, Volume and Issue: 67, P. 101423 - 101423

Published: June 25, 2024

Chronic hepatitis C virus (HCV) infection is a major cause of hepatic fibrosis and cirrhosis, with risk for the development hepatocellular carcinoma (HCC). Although highly effective direct-acting antivirals (DAAs) are available, incidence, morbidity, mortality HCV-associated HCC still high. This article reviews current knowledge mechanisms HCV-induced carcinogenesis special focus on those processes that continue after clearance outlines implications patient surveillance DAA treatment.

Language: Английский

Citations

9
Long-term serum ferritin dynamics in patients receiving antiviral treatment for hepatitis C virus infection DOI Creative Commons
Yu‐Ping Chang,

Chiuan-Bo Huang,

Jia‐Horng Kao

et al.

Journal of the Formosan Medical Association, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Limited data exists regarding the long-term serum ferritin dynamics following sustained virologic response (SVR12) and factors associated with trends in changes among patients undergoing treatment for hepatitis C virus (HCV). Serum levels were assessed biannually 1538 participants direct-acting antivirals (DAAs) or peginterferon plus ribavirin (PR) a median of follow-up 5.0 years after off-treatment week 12. We compared differences time-dependent slope coefficients interest using generalized estimating equations to identify predictors favorable evolution. Using univariable analysis, SVR12, aged ≤50 year, absence metabolic dysfunction-associated steatotic liver disease (MASLD), pre-treatment HCV RNA level ≤2,000,000 IU/mL Multivariable analysis showed that SVR12 (adjusted coefficient difference: 7.50 ng/mL/year [95% CI: 3.37 -11.63], p < 0.001) MASLD 4.16 7.91 -0.41], = 0.022) predicted Among achieving evolution was not affected by DAA PR (crude 3.33 12.78 6.12], 0.49). Absence 2.86 5.39 -0.33], 0.021). Patients irrespective types treatment, exhibited more those SVR12. may help improve

Language: Английский

Citations

1
Risk of de novo HCC in patients with MASLD following direct-acting antiviral-induced cure of HCV infection DOI
Chen‐Hua Liu, Pin‐Nan Cheng,

Yu‐Jen Fang

et al.

Journal of Hepatology, Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 1, 2024

Language: Английский

Citations

8
Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication DOI Creative Commons
Chung‐Feng Huang,

Manar Hijaze Awad,

Meital Gal-Tanamy

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: 30(3), P. 326 - 344

Published: April 26, 2024

Hepatitis C virus (HCV) infection is one of the major etiologies hepatocellular carcinoma (HCC) with approximately 30% HCC being due to HCV worldwide. eradication by antivirals greatly reduces risk HCC; nevertheless, remains occur in chronic hepatitis (CHC) patients who have achieved a sustained virological response (SVR). The proportion post-SVR among newly diagnosed increasing direct-acting antiviral (DAA) era and might be preexisting inflammatory fibrotic liver backgrounds, immune dysregulation between host interactions, as well epigenetic scars, genetic predispositions alternations. By means applying surrogate markers adopting stratification, surveillance should consistently performed high-risk populations. In this review, we discuss possible molecular mechanism, factors, strategy for development after CHC patients.

Language: Английский

Citations

6
Dynamic change of metabolic dysfunction-associated steatotic liver disease in patients with hepatitis C virus infection after achieving sustained virologic response with direct-acting antivirals DOI
Chen‐Hua Liu, Yu‐Ping Chang,

Yu‐Jen Fang

et al.

Journal of Gastroenterology, Journal Year: 2024, Volume and Issue: 59(7), P. 609 - 620

Published: April 13, 2024

Language: Английский

Citations

5
Dynamic change of metabolic dysfunction-associated steatotic liver disease in chronic hepatitis C patients after viral eradication: A nationwide registry study in Taiwan DOI Creative Commons
Chung‐Feng Huang, Chia‐Yen Dai,

Yi‐Hung Lin

et al.

Clinical and Molecular Hepatology, Journal Year: 2024, Volume and Issue: 30(4), P. 883 - 894

Published: July 29, 2024

Steatotic liver disease (SLD) is a common manifestation in chronic hepatitis C (CHC). Metabolic alterations CHC are associated with metabolic dysfunction-associated steatotic (MASLD). We aimed to elucidate whether virus (HCV) eradication mitigates MASLD occurrence or resolution. enrolled 5,840 patients whose HCV was eradicated by direct-acting antivirals nationwide registry. and the cardiometabolic risk factors (CMRFs) were evaluated at baseline 6 months after cure. There 2,147 (36.8%) SLD, 1,986 (34.0%) of them met criteria before treatment. After treatment, HbA1c (6.0% vs. 5.9%, P<0.001) BMI (24.8 kg/m2 24.7 kg/m2, decreased, whereas HDL-C (49.1 mg/dL 51.9 mg/dL, triglycerides (102.8 111.9 increased significantly. The proportion SLD 37.5% eradication, which did not change significantly compared pretreatment status. percentage who had post-treatment 34.8%, differ from status (P=0.17). Body mass index (BMI) (odds ratio [OR] 0.89; 95% confidence intervals [CI] 0.85-0.92; only factor In contrast, unfavorable CMRFs, including (OR 1.10; CI 1.06-1.14; 1.19; 1.04-1.35; P=0.01), independently development patients. CMRF surveillance mandatory for alterations, altered predict evolution MASLD.

Language: Английский

Citations

3
Dual-etiology MAFLD: the interactions between viral hepatitis B, viral hepatitis C, alcohol, and MAFLD DOI
Chun‐Jen Liu,

Wai Kay Seto,

Ming‐Lung Yu

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(S2), P. 897 - 908

Published: Aug. 8, 2024

Language: Английский

Citations

3
The interplay of metabolic dysfunction‐associated fatty liver disease and viral hepatitis on liver disease severity: A large community‐based study in a viral endemic area DOI
Chung‐Feng Huang, Po‐Cheng Liang, Pei‐Chien Tsai

et al.

Journal of Gastroenterology and Hepatology, Journal Year: 2023, Volume and Issue: 39(1), P. 193 - 201

Published: Sept. 20, 2023

Abstract Background and Aim The prevalence of metabolic dysfunction‐associated fatty liver disease (MAFLD) its interplay with hepatitis B virus (HBV) C (HCV) in terms severity is elusive. Methods A mass surveillance program was conducted a viral endemic area. objective to identify MAFLD/non‐MAFLD subjects advanced disease. Results Two thousand two hundred forty‐two (41.7%) the 5378 were identified as having MAFLD, 375 (7.0%) had proportions anti‐HCV HBsAg seropositivity 19.3% 9.7%, respectively. fibrosis non‐viral (NBNC), HBV HCV infection 2.8%, 5.7% 23.4%, Subjects MAFLD significantly higher proportion (8.7% vs 5.7%, P < 0.001). Factors associated included age (odds ratio [OR]/95% confidence interval [CI]: 4.8/3.7–6.0, 0.001), male sex (OR/CI: 1.3/1.0–1.7, = 0.019), 5.9/4.6–7.5, MAFLD‐lean dysregulation (MS) 2.6/1.3–5.2, 0.005; compared non‐MAFLD group) MAFLD‐diabetes 1.5/1.1–2.1, 0.008; group). did not aggravate patients hepatitis. However, among NBNC subjects, factors MS group 9.1/2.4–34.6, 0.001; MAFLD‐DM 2.0/1.2–3.2, 0.004; Conclusions diabetes risk effect more significant community level.

Language: Английский

Citations

4
The Influence of Treatment With Sofosbuvir/Velpatasvir on Children’s Growth—Results of the PANDAA-PED Study DOI
Maria Pokorska‐Śpiewak, Ewa Talarek, Małgorzata Aniszewska

et al.

The Pediatric Infectious Disease Journal, Journal Year: 2024, Volume and Issue: 44(1), P. 1 - 5

Published: Sept. 4, 2024

Background: The aim of this study was to evaluate the influence treatment hepatitis C with sofosbuvir and velpatasvir (SOF/VEL) on children’s growth. Methods: Fifty children 6-18 years age were successfully treated for a 12-week course SOF/VEL fixed dose adjusted body weight in PANDAA-PED (Treatment chronic 6–18 using pangenotypic direct-acting antiviral sofosbuvir/velpatasvir) project. Growth parameters compared at 1 year after baseline (at start treatment) 12-week-posttreatment values. Body mass index (BMI), height Z scores sex calculated according World Health Organization reference data. Results: Forty-nine participants (23 boys 26 girls) completed all visits. mean 10.9 ± 2.5 years, had undetectable virus RNA point. Significant gains observed irrespective patients’ sex. Height did not vary significantly both 12 weeks treatment, confirming normal increase participants’ height. Weight 16 below 10 decreased treatment. BMI score values boys, but no difference found between 1-year posttreatment girls boys. Conclusions: Results showed growth up successful age. Despite decrease differences Our observations confirm long-term safety

Language: Английский

Citations

1